Study #2023-0100
TRUDI: A phase II study of neoadjuvant Trastuzumab deruxtecan and Durvalumab (MEDI 4736) for stage III, HER2-expressing Inflammatory Breast Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Trastuzumab deruxtecan, Durvalumab
Description
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: * Trastuzumab deruxtecan * Durvalumab
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Study phase:
Phase II
Physician name:
Rachel Layman
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-844-898-4264
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.